Grupo de Investigación Pharmananogene

• Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JA, Isla A.  Population pharmacokientics of piperacillin and tazobactam in critically ill patients undergoing continous renal replacment therapy: application to pharmacokinetic/pharmacodynamic analysis Journal of Antimicrobial and Chemotherapy,  2014;  69,  180 - 189
• Calvo B. Author's Reply to Borg et al  Comment on: EU's New Pharmacovigilance Legislation: Considerations for Biosimilars Drug Safety,  2014;  37,  125 - 126
• Calvo B, Zuñiga L.  EU's New Pharmacovigilance Legislation: Considerations for Biosimilars Drug Safety,  2014;  37,  9 - 18
• Beloqui A, Solinís MA, Delgado A, Évora C, Isla A, Rodríguez-Gascón A.  Fate of Nanostructured Lipid Carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution Journal of Microencapulation,  2014;  31,  1 - 8
• Torrecilla J, Rodríguez-Gascón A, Solinís MÁ, del Pozo-Rodríguez A  Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives BioMed Research International,  2014;  2014
• Rodríguez-Gascón A, del Pozo-Rodríguez A, Solinís MÁ  Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. International Journal of Nanomedicine,  2014;  9,  1833 - 1843
• Beloqui A, Solinís MÁ, des Rieux A, Préat V, Rodríguez-Gascón A.  Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. International Journal of Pharmaceutics,  2014;  468,  105 - 111
• Lertxundi U, Domingo-Echaburu S, Irigoyen I, Isla A, Solinís MA, García-Moncó JC  Desafíos en el manejo farmacoterapéutico del paciente ingresado con enfermedad de Parkinson Revista de Neurología,  2014;  58,  353 - 364